Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025)

Spyre Therapeutics (SYRE) has disclosed Tax Provisions for 5 consecutive years, with -$15000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Tax Provisions fell 146.88% year-over-year to -$15000.0, compared with a TTM value of -$15000.0 through Dec 2025, down 129.41%, and an annual FY2025 reading of -$15000.0, down 129.41% over the prior year.
  • Tax Provisions was -$15000.0 for Q1 2025 at Spyre Therapeutics, down from $1000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $38000.0 in Q4 2022 and bottomed at -$209000.0 in Q3 2022.
  • Average Tax Provisions over 5 years is -$8583.3, with a median of $8000.0 recorded in 2022.
  • The sharpest move saw Tax Provisions tumbled 903.85% in 2022, then skyrocketed 500.0% in 2024.
  • Year by year, Tax Provisions stood at $23000.0 in 2021, then surged by 65.22% to $38000.0 in 2022, then tumbled by 92.11% to $3000.0 in 2023, then crashed by 66.67% to $1000.0 in 2024, then crashed by 1600.0% to -$15000.0 in 2025.
  • Business Quant data shows Tax Provisions for SYRE at -$15000.0 in Q1 2025, $1000.0 in Q4 2024, and $18000.0 in Q3 2024.